文献速递糖尿病肥胖与代谢综合征

一种改善细胞和高脂饮食小鼠模型高血糖及脂肪蓄积的抗纤维化化合物

An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models.
PubMed 文献 · Diabetologia · 2024-09-09

本研究在L6-GLUT4、HepG2和3T3-L1细胞及高脂饮食(HFD)小鼠中评估化合物HPH-15的作用。HPH-15在10 µmol/l浓度下激活AMPK、促进葡萄糖摄取和GLUT4膜转位,效果与2 mmol/l二甲双胍相当;在HFD小鼠中降低血糖、改善胰岛素抵抗、抑制脂肪蓄积和纤维化,高剂量还使皮下脂肪减少44%。

要点

  • HPH-15在10 µmol/l浓度下激活AMPK、促进葡萄糖摄取和GLUT4膜转位,效果与2 mmol/l二甲双胍相当。
  • HFD小鼠中HPH-15降低血糖并改善胰岛素抵抗,10 mg/kg组AMPK激活程度与300 mg/kg二甲双胍组相同。
  • HPH-15抑制HFD小鼠肝脏和脂肪组织的脂肪蓄积与纤维化,效果比二甲双胍更显著;高剂量使皮下脂肪减少44%。

核心结论

  • HPH-15在体外和体内以低于二甲双胍的浓度激活AMPK,并在体内改善血糖水平和胰岛素抵抗。
  • HPH-15在改善HFD小鼠脂肪肝和脂肪细胞肥大方面比二甲双胍更有效。
  • HPH-15可能有效预防脂肪肝,后者是糖尿病个体常见的并发症。
  • 与二甲双胍不同,高剂量HPH-15减少HFD小鼠的皮下脂肪。
  • HPH-15可能是一种降低血糖、抑制脂肪蓄积和改善肝纤维化的降糖药物。

研究设计与样本

  • 体外研究使用L6-GLUT4、HepG2和3T3-L1细胞,分别作为肌肉、肝脏和脂肪组织的模型。
  • 体内研究使用高脂饮食(HFD)喂养的小鼠,评估HPH-15的降糖、抑制脂肪蓄积、抗纤维化和AMPK激活作用。

主要发现

  • HPH-15在10 µmol/l浓度下增加各细胞模型的AMPK激活、葡萄糖摄取和GLUT4膜转位,程度与2 mmol/l二甲双胍相同。
  • HPH-15处理细胞中乳酸生成等于或少于二甲双胍处理细胞。
  • HFD小鼠中,HPH-15使血糖从11.1±0.3 mmol/l降至8.2±0.4 mmol/l(10 mg/kg)和7.9±0.4 mmol/l(100 mg/kg),并改善胰岛素抵抗。
  • HPH-15(10 mg/kg)组在所有器官中AMPK激活水平与二甲双胍(300 mg/kg)组相同。
  • HPH-15处理的HFD小鼠肝脏和脂肪组织脂肪蓄积和纤维化受到抑制,效果比二甲双胍更显著;高剂量HPH-15使皮下脂肪减少44%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Appropriate management of blood glucose levels and the prevention of complications are important in the treatment of diabetes. We have previously reported on a compound named HPH-15 that is not only antifibrotic but also AMP-activated protein kinase (AMPK)-activating. In this study, we evaluated whether HPH-15 is useful as a therapeutic medication for diabetes. METHODS: We examined the effects of HPH-15 on AMPK activation, glucose uptake, fat accumulation and lactic acid production in L6-GLUT4, HepG2 and 3T3-L1 cells, as a model of muscle, liver and fat tissue, respectively. Additionally, we investigated the glucose-lowering, fat-accumulation-suppressing, antifibrotic and AMPK-activating effect of HPH-15 in mice fed a high-fat diet (HFD). RESULTS: HPH-15 at a concentration of 10 µmol/l increased AMPK activation, glucose uptake and membrane translocation of GLUT4 in each cell model to the same extent as metformin at 2 mmol/l. The production of lactic acid (which causes lactic acidosis) in HPH-15-treated cells was equal to or less than that observed in metformin-treated cells. In HFD-fed mice, HPH-15 lowered blood glucose from 11.1±0.3 mmol/l to 8.2±0.4 mmol/l (10 mg/kg) and 7.9±0.4 mmol/l (100 mg/kg) and improved insulin resistance. The HPH-15 (10 mg/kg) group showed the same level of AMPK activation as the metformin (300 mg/kg) group in all organs. The HPH-15-treated HFD-fed mice also showed suppression of fat accumulation and fibrosis in the liver and fat tissue; these effects were more significant than those obtained with metformin. Mice treated with high doses of HPH-15 also exhibited a 44% reduction in subcutaneous fat. CONCLUSIONS/INTERPRETATION: HPH-15 activated AMPK at lower concentrations than metformin in vitro and in vivo and improved blood glucose levels and insulin resistance in vivo. In addition, HPH-15 was more effective than metformin at ameliorating fatty liver and adipocyte hypertrophy in HFD-fed mice. HPH-15 could be effective in preventing fatty liver, a common complication in diabetic individuals. Additionally, in contrast to metformin, high doses of HPH-15 reduced subcutaneous fat in HFD-fed mice. Presumably, HPH-15 has a stronger inhibitory effect on fat accumulation and fibrosis than metformin, accounting for the reduction of subcutaneous fat. Therefore, HPH-15 is potentially a glucose-lowering medication that can lower blood glucose, inhibit fat accumulation and ameliorate liver fibrosis.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Toma T, Miyakawa N, Arakaki Y, et al. An antifibrotic compound that ameliorates hyperglycaemia and fat accumulation in cell and HFD mouse models. Diabetologia. 2024. PMID: 39251430. doi:10.1007/s00125-024-06260-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。